Cilgavimab

Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab . Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection.

Cilgavimab and Tixagevimab simultaneously bind to distinct, nonoverlapping epitopes of the SARS-CoV-2 spike-protein (S) receptor-binding domain to potently neutralize the virus^[1].
Cilgavimab exhibits potent monoclonal antibody neutralization activity, and human ACE2-blocking activity, with IC₅₀s of 10-150 ng/mL, and shows binding ability to either trimeric S2Pecto protein or monomeric SRBD with IC₅₀s of 0.1-10 ng/mL^[2].

Cilgavimab (200 μg/mouse; i.p.; before SARS-CoV-2 injection) protects mice from weight loss and reduces the viral burden and levels of inflammation in the lungs^[2].

References:
[1]. Levin MJ, et al; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188-2200.
[2]. Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 Aug;584(7821):443-449.